Cargando…

Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial

OBJECTIVE: To evaluate long‐term safety/tolerability of brivaracetam at individualized doses ≤200 mg/d (primary) and maintenance of efficacy over time (secondary) in adults with focal seizures or primary generalized seizures (PGS) enrolled in phase 3, open‐label, long‐term follow‐up trial N01199 (NC...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Brien, Terence J., Borghs, Simon, He, Qin (Jane), Schulz, Anne‐Liv, Yates, Stephen, Biton, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384045/ https://www.ncbi.nlm.nih.gov/pubmed/32221987 http://dx.doi.org/10.1111/epi.16484

Ejemplares similares

Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers
por: Lerche, Holger, et al.
Publicado: (2020)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Open‐label long‐term treatment of add‐on triheptanoin in adults with drug‐resistant epilepsy
por: Borges, Karin, et al.
Publicado: (2020)

Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
por: Niquet, Jerome, et al.
Publicado: (2017)

A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
por: Finnema, Sjoerd J., et al.
Publicado: (2019)

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022)

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
por: Swallow, Elyse, et al.
Publicado: (2017)

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
por: Mukuria, Clara, et al.
Publicado: (2016)

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
por: Wheless, James W., et al.
Publicado: (2021)

Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
por: Borges, Karin, et al.
Publicado: (2019)

Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design
por: Bast, Thomas, et al.
Publicado: (2022)

Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long‐term, open‐label safety study
por: Segal, Eric B., et al.
Publicado: (2021)

Time course of 75%–100% efficacy response of adjunctive brivaracetam
por: Klein, Pavel, et al.
Publicado: (2020)

Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study
por: French, Jacqueline A., et al.
Publicado: (2021)

Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta‐analyses and real‐world evidence on antiepileptic drugs
por: Thieffry, Solène, et al.
Publicado: (2020)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study
por: Sperling, Michael R., et al.
Publicado: (2020)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2022)

Cathodal transcranial direct‐current stimulation for treatment of drug‐resistant temporal lobe epilepsy: A pilot randomized controlled trial
por: Zoghi, Maryam, et al.
Publicado: (2016)

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
por: Lattanzi, Simona, et al.
Publicado: (2022)

Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials
por: Ryvlin, Philippe, et al.
Publicado: (2022)

Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy
por: Tolbert, Dwain, et al.
Publicado: (2015)

Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
por: Zahnert, Felix, et al.
Publicado: (2018)

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study
por: Sperling, Michael R., et al.
Publicado: (2021)

Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study
por: Wechsler, Robert T, et al.
Publicado: (2014)

The provision of epilepsy care across Europe 2017: A 17‐year follow‐up survey
por: Zelano, Johan, et al.
Publicado: (2019)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)
por: Yamamoto, Takamichi, et al.
Publicado: (2020)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Emerging drugs for partial-onset epilepsy: a review of brivaracetam
por: Gao, Lan, et al.
Publicado: (2016)

New developments in the management of partial-onset epilepsy: role of brivaracetam
por: Coppola, Giangennaro, et al.
Publicado: (2017)

Brivaracetam in the treatment of epilepsy: a review of clinical trial data
por: Feyissa, Anteneh M
Publicado: (2019)

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
por: Rosenfeld, William E., et al.
Publicado: (2021)

Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer
por: Larki, Pegah, et al.
Publicado: (2018)

Open-Label Placebo Treatment: Outcome Expectations and General Acceptance in the Lay Population
por: Haas, Julia W., et al.
Publicado: (2020)

Hippocampal Expression of Connexin36 and Connexin43 during Epileptogenesis in Pilocarpine Model of Epilepsy
por: Motaghi, Sahel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_drmsnktvchpqmlhhp4c36ng68u